NEW YORK (GenomeWeb News) – NeoGenomics today announced the public offering of 3.15 million shares of its common stock at $3.00 per share.

The Ft. Myers, Fla.-based firm which specializes in cancer genetic testing, is selling 2.85 million shares, while a shareholder, the Mary S. Dent Gifting Trust, will sell 300,000 shares.

NeoGenomics expects to raise $7.8 million in net proceeds from the offering. It will not receive any proceeds from Mary S. Dent's sale of its shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.